CAR T-cell therapy is a cancer treatment in which a patient's own T cells, a type of immune cell, are removed from the blood and genetically engineered to carry a chimeric antigen receptor, or CAR, that lets the modified cells recognize and attack cancer cells bearing a specific target antigen. The engineered cells, grown in large numbers outside the body, are then infused back into the patient, where they act as what researchers have called a living drug, multiplying and attacking tumor cells that carry the targeted antigen. Because the receptor is engineered to bind an antigen expressed on the tumor but ideally not on healthy tissue, CAR T-cell therapy is designed to concentrate its effect on cancer cells while limiting damage to normal cells, though it remains a complex, individually manufactured treatment used mainly for certain blood cancers.
Facts
Disputed
Origin YearThe chimeric receptor concept was described in 1987 and first entered clinical trial in the mid-1990s; this fact records 2017, the year the FDA granted the first two CAR T-cell therapy approvals (tisagenlecleucel and axicabtagene ciloleucel), the point the treatment became a real available therapy rather than an experimental construct. Connections
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia FoundationCAR T cell - History and regulatory approval section
These trials ultimately led in the US to the FDA's first two approvals of CAR T cells in 2017, those for tisagenlecleucel (Kymriah)...and axicabtagene ciloleucel (Yescarta)
- Clinical use status
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.